Akari Therapeutics says AKTX-101 shows anti-tumor activity in preclinical urothelial cancer models
Reuters2026/08/18 12:53- Akari reported new preclinical urothelial cancer data for AKTX-101, a TROP2-targeted ADC using its PH1 RNA splicing modulator payload.
- AKTX-101 showed statistically significant tumor growth inhibition in the UM-UC-14 metastatic urothelial carcinoma model where Padcev had limited response.
- Switching Trodelvy-resistant tumors to AKTX-101 slowed growth, supporting activity in topoisomerase I payload-resistant disease.
- Results bolster a differentiated ADC sequencing strategy as prior exposure increases, targeting resistance seen with microtubule or topoisomerase I payloads.
- IND-enabling work continues, with a Phase 1 trial start targeted for mid-2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SmartStop Self Storage REIT Price Target Raised to $39.25/Share From $38.50 by National Bank
AutoCanada Profitability Seen Normalizing by 4Q -- Market Talk
Strategists warn: Gamma is extremely unstable! U.S. stocks with "ultra-low correlation" are facing the risk of violent shocks
This year, the low correlation in the U.S. stock market has been mainly driven by leading AI companies, but capital is shifting from semiconductor sectors towards lagging areas such as SaaS, narrowing the dispersion and weakening the foundation for low correlation. Bloomberg strategists warn that under abnormal Gamma volatility, a turn to negative could cause options dealers to reverse their hedging direction, amplifying market fluctuations. While the current index is less than 1% below its high, a 3% to 4% pullback could trigger a sharp Gamma reversal, putting the seemingly calm market at risk of dramatic volatility.
Web3: Bitcoin under pressure as miners, ETF, and strategy buying slow down
